Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 48-week SAR448851 Treatment Followed by Open-label Extension in Participants With Early Alzheimer's Disease

NCT07688213 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07688213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07688213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 48-week SAR448851 Treatment Followed by Open-label Extension in Participants With Early Alzheimer's Disease
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Recruiting
Start date
July 28, 2026
Completion date
July 31, 2029
Enrollment
160 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, dementia, alzheimer's type